Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from REGN

Buy the Dip in 3 Top-Rated Large-Cap Stocks

The increasing economic sanctions on Russia and consequent surge in oil prices and supply-chain disruptions will surely keep the stock market under pressure. Therefore, we think it could be wise to buy the price dip in quality large-cap stocks Regeneron Pharmaceuticals (REGN), Telefonaktiebolaget LM Ericsson (ERIC), and PPG Industries (PPG)…

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned

Recap: Regeneron Pharmaceuticals Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Earnings Preview For Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will likely report an Earnings Per Share (EPS) of $18.11.

Analyst Ratings For Regeneron Pharmaceuticals

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

1 2 3 4 5

Organisations

Regeneron Pharmaceuticals

Eli Lilly And Co

Regeneron Pharmaceuticals Inc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

375,183 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play